Annais Troncoso
Nurse Practitioner · Imperial, CANPI 1568050169
Payments from drug & device makers
Across 121 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Globus Medical$414
- MDD US Operations, LLC$323
- Corcept Therapeutics$240
- Neurocrine Biosciences, Inc.$204
- Biohaven Pharmaceutical Holding Company Ltd.$193
- AstraZeneca$187
- plus $999 from 23 others
What the payments were for
- Food & beverage$2,559100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Globus Medical | 12 | $414 |
| MDD US Operations, LLC | 17 | $323 |
| Corcept Therapeutics | 6 | $240 |
| Neurocrine Biosciences, Inc. | 12 | $204 |
| Biohaven Pharmaceutical Holding Company Ltd. | 18 | $193 |
| AstraZeneca | 5 | $187 |
| AbbVie | 9 | $167 |
| Acadia Pharmaceuticals Inc | 6 | $125 |
| Biogen | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| Neurelis, Inc. | 4 | $67 |
| Shield Therapeutics Inc | 1 | $59 |
| Pfizer | 3 | $48 |
| Stimwave Technologies Incorporated | 1 | $47 |
| Eisai Inc. | 2 | $42 |
| Averitas Pharma Inc. | 1 | $36 |
| Boehringer Ingelheim | 1 | $30 |
| Amgen | 2 | $29 |
| Amneal Pharmaceuticals LLC | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Corium, LLC | 1 | $22 |
| Nevro Corp. | 1 | $21 |
| Seqirus USA Inc | 1 | $19 |
| UCB, Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Bayer | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Tandem Diabetes Care, Inc. | 3 | $14 |
| SPR Therapeutics, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,559 in reported general payments places this provider in the 90th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NamzaricMemantine Hcl/Donepezil Hcl | 270 | $191,838 |
| Nurtec OdtRimegepant Sulfate | 75 | $111,547 |
| AptiomEslicarbazepine Acetate | 59 | $106,990 |
| UbrelvyUbrogepant | 88 | $95,994 |
| EliquisApixaban | 140 | $91,463 |
| XareltoRivaroxaban | 67 | $43,719 |
| Aimovig AutoinjectorErenumab-Aooe | 29 | $41,413 |
| QuliptaAtogepant | 36 | $39,619 |
| Emgality PenGalcanezumab-Gnlm | 23 | $28,806 |
| Memantine Hcl | 1,350 | $25,659 |
| Diclofenac Sodium | 406 | $23,840 |
| Lidocaine | 252 | $23,672 |
| Buprenorphine | 107 | $23,557 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 821 | $19,981 |
| Memantine Hcl ErMemantine Hcl | 234 | $18,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieNamzaric, Ubrelvy, Qulipta | $167 | $327,451394 claims |
| PfizerNurtec Odt, Eliquis | $48 | $203,010215 claims |
| Johnson & JohnsonXarelto | $15 | $43,71967 claims |
| Neurelis, Inc.Valtoco | $67 | $16,68515 claims |
| AstraZenecaBrilinta | $187 | $10,02020 claims |
| Amneal Pharmaceuticals LLCRytary | $25 | $9,16717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Imperial
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
- Angelina CollinsSan Diego$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.